Loading
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Latest filing published 08 Sept 2026 for HLS Therapeutics Inc., €4,632. Read the official filing
Insider track record
Disclosed buys
3
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
John Gordon Hanna: trading record in brief
All filings by John Gordon Hanna on record concern HLS Therapeutics Inc. In total, 6 filings cover trades dated from 21 June 2023 to 1 September 2026.
Every open-market trade on record is a purchase: 3 purchases worth €27k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 1 share grant. In 2026 alone, the filings show 2 purchases and no sales.
The median purchase comes to €11k. No cluster: in 3 purchases, no other insider of the company bought within 30 days.
The latest filing, published on 8 September 2026, reports an open-market purchase of €4,632 in HLS Therapeutics Inc. The median gap between a trade and its publication by SEDI is 6 days. That lag is the time during which only the insider knows about the trade. Source: insider filings from SEDI. Past trades are no guide to future returns.
Companies and markets linked to John Gordon Hanna
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
2,000 shares@ CA$3.728Common SharesTSXSEDI:4774721
50,000 shares@ CA$4.140.17% mcap92.4% of flowRestricted Share UnitsTSXSEDI:4741926
Restricted Share UnitsTSXSEDI:4741925
4,000 shares@ CA$4.30100.0% of flowCommon SharesTSXSEDI:4736753
4 of 4 declarations
